ImageneBio Inc

IMA | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.92

+$0.11 (+2.29%)

Sep 22, 2026, 1:56 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Key Executives

Name	Position
Kristin Yarema	CEO & Director
Benjamin Porter-Brown	Chief Medical Officer
Bob Lally	Senior VP of Finance & Operations and Principal Accounting Officer
Kurinji Pandiyan	Chief Strategy & Operations Officer
Matt Robbins	General Counsel
Renuka Sivendran	Chief Technical Officer
Robert Lally	Senior VP of Finance & Operations and Principal Accounting Officer
Yanina Grant-Huerta	CFO, Principal Financial Officer & Principal Accounting Officer

Latest SEC Filings

Date	Type	Title
Aug 17, 2026	4	Filing
Aug 17, 2026	4	Filing
Aug 14, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Aug 11, 2026	EFFECT	Filing
Aug 11, 2026	EFFECT	Filing
Aug 06, 2026	EFFECT	Filing
Aug 05, 2026	S-8	Filing
Aug 05, 2026	S-3	Filing
Aug 05, 2026	POS AM	Filing
Aug 05, 2026	424B3	Filing

View All SEC Filings ➞

ImageneBio Inc

Country	United States
IPO Date	Feb 26, 1998
Industry	Biotechnology
Sector	Healthcare
Employees	18
CEO	Kristin Yarema

Contact Details

12526 High Bluff Drive, Suite 345, San Diego, CA 92130 San Diego, California 92130 United States

https://www.inmagenebio.com

858 345 6265

Stock Details

Ticker Symbol	IMA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001835579
CUSIP Number	45175G207
ISIN Number	US45175G2075
SIC Code	2836